GlassScriptPhysician profile
James J Maly
NPI 1700872025
$1,212.53
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $763 · 2020: $37.68 · 2021: $75.13 · 2022: $80.60 · 2023: $108 · 2024: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $143 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $142.67 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $113.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tosoh Bioscience, INC. | $628.00 | 2019 | |
| Abbvie INC. | $250.67 | 2019-2024 | |
| Astellas Pharma US INC | $110.37 | 2023-2024 | Veozah |
| Intuitive Surgical, INC. | $81.27 | 2019 | |
| Pfizer INC. | $34.39 | 2021-2023 | |
| Allergan, INC. | $24.18 | 2020 | |
| Avion Pharmaceuticals | $20.45 | 2022 | |
| Merck Sharp & Dohme LLC | $16.93 | 2019 | |
| Baxter Healthcare | $16.47 | 2021 | |
| Evofem Biosciences, INC. | $16.30 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.50 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Maly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.